BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 9248321)

  • 1. [Present status of donor leukocyte transfusion for leukemia. Relapse after allogeneic bone marrow transplantation in Japan].
    Morishima Y; Kodera Y
    Rinsho Ketsueki; 1997 Jun; 38(6):476-8. PubMed ID: 9248321
    [No Abstract]   [Full Text] [Related]  

  • 2. Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome.
    Shiobara S; Nakao S; Ueda M; Yamazaki H; Takahashi S; Asano S; Yabe H; Kato S; Imoto S; Maruta A; Yoshida T; Gondo H; Morishima Y; Kodera Y
    Bone Marrow Transplant; 2000 Oct; 26(7):769-74. PubMed ID: 11042659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Therapeutic effect of donor leukocyte transfusion in relapsing marrow transplants in Japan].
    Shiobara S; Takahasi S; Yabe H; Maruta I; Kodera Y
    Rinsho Ketsueki; 1997 Nov; 38(11):1162-9. PubMed ID: 9423332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells.
    Verdonck LF; Petersen EJ; Lokhorst HM; Nieuwenhuis HK; Dekker AW; Tilanus MG; de Weger RA
    Bone Marrow Transplant; 1998 Dec; 22(11):1057-63. PubMed ID: 9877267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular remission induced by fractionated dose-escalating donor leukocyte infusion without graft-versus-host disease in a patient with chronic myelogenous leukemia relapsed after allogeneic bone marrow transplantation.
    Inai K; Wano Y; Yamamoto S; Ikebata Y; Iwasaki H; Tsutani H; Naiki H; Ueda T
    Anticancer Res; 1999; 19(6C):5631-4. PubMed ID: 10697631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of induced GVHD in leukemia patients relapsing after allogeneic bone marrow transplantation: single-center experience of 33 adult patients.
    Min CK; Eom KS; Lee S; Kim DW; Lee JW; Min WS; Kim CC
    Bone Marrow Transplant; 2001 May; 27(9):999-1005. PubMed ID: 11436112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Leukocyte transfusion as therapy of recurrent CML after allogenic bone marrow transplantation].
    Wiesneth M; Hertenstein B; Bunjes D; Novotny J; Stefanic M; Heinze B; Schreiner T; Kubanek B; Heimpel H; Arnold R
    Beitr Infusionsther Transfusionsmed; 1994; 32():276-80. PubMed ID: 9480108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Donor leukocyte transfusion for relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation].
    Murata R; Shiohara S; Nakao S
    Rinsho Ketsueki; 2000 Apr; 41(4):288-91. PubMed ID: 10846457
    [No Abstract]   [Full Text] [Related]  

  • 9. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
    Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
    Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Donor leukocyte transfusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation].
    Itoh T; Hatta Y; Miyajima T; Simojima H; Sawada U; Horie T
    Rinsho Ketsueki; 1998 Jun; 39(6):409-15. PubMed ID: 9695667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allogeneic peripheral blood progenitor cells for treatment of relapse after bone marrow transplantation.
    Glass B; Majolino I; Dreger P; Scimè R; Santoro A; Vasta S; Suttorp M; Haferlach T; Schmitz N
    Bone Marrow Transplant; 1997 Oct; 20(7):533-41. PubMed ID: 9337054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Donor leukocyte transfusion in a patient with relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation: analysis of natural killer cell activity and T-cell receptor repertoire in bone marrow T cells that exhibited graft-versus-leukemia activity].
    Suehiro Y; Muta K; Umemura T; Motomura S; Nishimura J; Nawata H; Kimura N
    Rinsho Ketsueki; 1999 Jan; 40(1):40-5. PubMed ID: 10067095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term follow-up of patients who achieved complete remission after donor leukocyte infusions.
    Porter DL; Collins RH; Shpilberg O; Drobyski WR; Connors JM; Sproles A; Antin JH
    Biol Blood Marrow Transplant; 1999; 5(4):253-61. PubMed ID: 10465105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Graft-versus-leukemia effects from donor lymphocyte infusion after nonmyeloablative allogeneic bone marrow transplantation in mice.
    Du B; Li DP; Xu KL; Pan XY
    Chin Med J (Engl); 2005 Mar; 118(6):474-9. PubMed ID: 15788128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Helper T-lymphocyte precursor frequency predicts the occurrence of graft-versus-host disease and disease relapse after allogeneic bone marrow transplantation from HLA-identical siblings.
    Leung AY; Kwok J; Lie AK; Chen P; Chen FE; Liang R
    Haematologica; 2001 Jun; 86(6):652-6. PubMed ID: 11418376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transfusion of donor buffy coat cells in the treatment of persistent or recurrent malignancy after allogeneic bone marrow transplantation.
    Collins RH; Pineiro LA; Nemunaitis JJ; Jain VK; Waxman D; Miller WV; Fay JW
    Transfusion; 1995; 35(11):891-8. PubMed ID: 8604484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone marrow vs extramedullary relapse of acute leukemia after allogeneic hematopoietic cell transplantation: risk factors and clinical course.
    Lee KH; Lee JH; Choi SJ; Lee JH; Kim S; Seol M; Lee YS; Kim WK; Seo EJ; Park CJ; Chi HS; Lee JS
    Bone Marrow Transplant; 2003 Oct; 32(8):835-42. PubMed ID: 14520431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.
    Li JM; Waller EK
    Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of a graft-versus-leukemia reaction by cyclosporin A withdrawal as immunotherapy for leukemia relapsing after allogeneic bone marrow transplantation.
    Elmaagacli AH; Beelen DW; Trenn G; Schmidt O; Nahler M; Schaefer UW
    Bone Marrow Transplant; 1999 Apr; 23(8):771-7. PubMed ID: 10231138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Donor leukocyte infusions after unrelated donor hematopoietic stem cell transplantation.
    Loren AW; Porter DL
    Curr Opin Oncol; 2006 Mar; 18(2):107-14. PubMed ID: 16462177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.